Market closed

Summit Therapeutics/$SMMT

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Summit Therapeutics

Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Ticker

$SMMT

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Miami, United States

Employees

105

Website

www.summittxinc.com

SMMT Metrics

BasicAdvanced

$14B

Market cap

-

P/E ratio

-$0.28

EPS

-0.92

Beta

-

Dividend rate

Price and volume

Market cap

$14B

Beta

-0.92

52-week high

$28.73

52-week low

$2.10

Average daily volume

1.9M

Financial strength

Current ratio

8.309

Quick ratio

8.262

Long term debt to equity

0.961

Total debt to equity

7.421

Interest coverage (TTM)

-15.69%

Management effectiveness

Return on assets (TTM)

-31.45%

Return on equity (TTM)

-73.20%

Valuation

Price to book

30.97

Price to tangible book (TTM)

31.11

Price to free cash flow (TTM)

-101.97

Growth

Earnings per share change (TTM)

-74.54%

3-year earnings per share growth (CAGR)

-31.35%

What the Analysts think about SMMT

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Summit Therapeutics stock.

SMMT Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

SMMT Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

SMMT News

AllArticlesVideos

Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire·1 week ago

Summit Therapeutics Stock Set To Soar By Mid-2025 On HARMONi Phase 3 Trial

Seeking Alpha·3 weeks ago

Summit Therapeutics to Present at Upcoming Investor Conferences

Business Wire·4 weeks ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SMMT

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Summit Therapeutics stock?

Summit Therapeutics (SMMT) has a market cap of $14B as of December 21, 2024.

What is the P/E ratio for Summit Therapeutics stock?

The price to earnings (P/E) ratio for Summit Therapeutics (SMMT) stock is 0 as of December 21, 2024.

Does Summit Therapeutics stock pay dividends?

No, Summit Therapeutics (SMMT) stock does not pay dividends to its shareholders as of December 21, 2024.

When is the next Summit Therapeutics dividend payment date?

Summit Therapeutics (SMMT) stock does not pay dividends to its shareholders.

What is the beta indicator for Summit Therapeutics?

Summit Therapeutics (SMMT) has a beta rating of -0.92. This means that it has an inverse relation to market volatility.